1. Home
  2. BIIB
  3. BIIB News

Latest Biogen Inc. (BIIB) News on July 27, 2024

Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
BIIB

Investor's Business Daily

5 hours ago

Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug

BIIB

MT Newswires

10 hours ago

RBC Capital Adjusts Price Target on Biogen to $282 From $303

EU Rejection of Alzheimer’s Drug Is Another Disappointment for Biogen
BIIB

Barrons.com

10 hours ago

EU Rejection of Alzheimer’s Drug Is Another Disappointment for Biogen

Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
BIIB

Benzinga

11 hours ago

Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events

BIIB

MT Newswires

11 hours ago

Baird Adjusts Price Target on Biogen to $294 From $316

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
BIIB

Zacks

11 hours ago

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical

European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval
BIIB

Associated Press Finance

11 hours ago

European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval

BIIB

MT Newswires

13 hours ago

Biogen Shares Drop After EMA Panel's Negative Opinion on Alzheimer's Disease Drug

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
BIIB

GlobeNewswire

14 hours ago

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
BIIB

Zacks

a day ago

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for

Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial
BIIB

Clinical Trials Arena

2 days ago

Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
BIIB

Investor's Business Daily

2 days ago

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails

BIIB

MT Newswires

2 days ago

Sage Therapeutics, Biogen Stop Development of Investigational Drug for Essential Tremor

Sage Therapeutics Stock Slides as Pipeline Thins
BIIB

Barrons.com

2 days ago

Sage Therapeutics Stock Slides as Pipeline Thins

Is Biogen (BIIB) an Underappreciated Stock?
BIIB

Insider Monkey

2 days ago

Is Biogen (BIIB) an Underappreciated Stock?

Biogen, Sage tremor drug fails key trial
BIIB

BioPharma Dive

3 days ago

Biogen, Sage tremor drug fails key trial

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
BIIB

Business Wire

3 days ago

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

Nanotechnology in medicine: Who are the leading public companies?
BIIB

Medical Device Network

4 days ago

Nanotechnology in medicine: Who are the leading public companies?

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
BIIB

Investor's Business Daily

4 days ago

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Ionis plots next steps for Angelman drug Biogen passed on
BIIB

BioPharma Dive

5 days ago

Ionis plots next steps for Angelman drug Biogen passed on

Sage Therapeutics/Biogen’s episodic therapy zuranolone could change MDD treatment
BIIB

Clinical Trials Arena

5 days ago

Sage Therapeutics/Biogen’s episodic therapy zuranolone could change MDD treatment

Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
BIIB

Zacks

7 days ago

Ionis (IONS) Completes Enrolment for Rare Disease Drug Study

Is Eli Lilly Stock A Sell On A Rare Stumble In Obesity Treatment?
BIIB

Investor's Business Daily

8 days ago

Is Eli Lilly Stock A Sell On A Rare Stumble In Obesity Treatment?

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
BIIB

Zacks

9 days ago

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

Three Surprising Names That Could Be On Biogen's Buyout Shortlist
BIIB

Investor's Business Daily

10 days ago

Three Surprising Names That Could Be On Biogen's Buyout Shortlist

BIIB

MT Newswires

10 days ago

Biogen Needs Revenue-Generating Assets to Complete Turnaround, Wedbush Says

BIIB

MT Newswires

11 days ago

Redburn Atlantic Adjusts Price Target on Biogen to $230 From $235, Maintains Neutral Rating

BIIB

MT Newswires

11 days ago

Goldman Sachs Adjusts Price Target on Biogen to $342 From $340, Maintains Buy Rating

BIIB

MT Newswires

14 days ago

Biogen, Eisai Get Approval for Leqembi in Israel for Treatment of Alzheimer's Disease

Eli Lilly Overcomes Biden-Tied Stumble To Rise Again — Is Lilly Stock Now A Buy?
BIIB

Investor's Business Daily

15 days ago

Eli Lilly Overcomes Biden-Tied Stumble To Rise Again — Is Lilly Stock Now A Buy?

BIIB

MT Newswires

15 days ago

Piper Sandler Adjusts Biogen's Price Target to $313 From $335, Keeps Overweight Rating

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
BIIB

Zacks

15 days ago

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

BIIB

MT Newswires

16 days ago

Morgan Stanley Adjusts Price Target on Biogen to $311 From $331

BIIB

MT Newswires

16 days ago

Biogen, Eisai Say Alzheimer's Drug Leqembi Secures Regulatory Approval in Hong Kong

BIIB

MT Newswires

18 days ago

RBC Cuts Price Target on Biogen to $303 From $317, Keeps Outperform Rating

Top Stock Movers Now: Tesla, Paramount Global, Biogen, and More
BIIB

Investopedia

23 days ago

Top Stock Movers Now: Tesla, Paramount Global, Biogen, and More

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
BIIB

Pharmaceutical Technology

23 days ago

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Biden Just Knocked Eli Lilly Stock Off Its Pedestal — Is It A Buy Or A Sell?
BIIB

Investor's Business Daily

24 days ago

Biden Just Knocked Eli Lilly Stock Off Its Pedestal — Is It A Buy Or A Sell?

Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug
BIIB

Investor's Business Daily

24 days ago

Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug

BIIB

MT Newswires

24 days ago

US Equities Markets End Higher Tuesday Following Fed Chair Powell's Comments

Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
BIIB

Insider Monkey

24 days ago

Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth

BIIB

MT Newswires

24 days ago

Biogen Closes Human Immunology Biosciences Acquisition

Biogen Completes Acquisition of Human Immunology Biosciences
BIIB

GlobeNewswire

24 days ago

Biogen Completes Acquisition of Human Immunology Biosciences

10 clinical trials to watch in the second half of 2024
BIIB

BioPharma Dive

a month ago

10 clinical trials to watch in the second half of 2024

Eisai and Biogen launch LEQEMBI for Alzheimer’s in China
BIIB

Pharmaceutical Technology

a month ago

Eisai and Biogen launch LEQEMBI for Alzheimer’s in China

BIIB

MT Newswires

a month ago

Biogen, Eisai Launch Leqembi in China to Treat Alzheimer's Disease

Eisai and Biogen launch Alzheimer's drug Leqembi in China
BIIB

Reuters

a month ago

Eisai and Biogen launch Alzheimer's drug Leqembi in China

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
BIIB

GlobeNewswire

a month ago

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

Eli Lilly Has Sprinted 55% Higher This Year — Is It A Buy On The Weight-Loss Opportunity?
BIIB

Investor's Business Daily

a month ago

Eli Lilly Has Sprinted 55% Higher This Year — Is It A Buy On The Weight-Loss Opportunity?

FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
BIIB

Zacks

a month ago

FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen

Pharma M&A: The top high value deals in 2023
BIIB

Pharmaceutical Technology

a month ago

Pharma M&A: The top high value deals in 2023

Is the Options Market Predicting a Spike in Biogen (BIIB) Stock?
BIIB

Zacks

a month ago

Is the Options Market Predicting a Spike in Biogen (BIIB) Stock?

Biogen Inc. (BIIB) is a Top-Ranked Momentum Stock: Should You Buy?
BIIB

Zacks

a month ago

Biogen Inc. (BIIB) is a Top-Ranked Momentum Stock: Should You Buy?

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
BIIB

GlobeNewswire

a month ago

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
BIIB

Zacks

a month ago

Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug

Two Is Better Than One in the Alzheimer’s Market
BIIB

The Wall Street Journal

a month ago

Two Is Better Than One in the Alzheimer’s Market

ALS pipeline suffers a major hit as Biogen’s Tofersen fails phase iii trial
BIIB

Clinical Trials Arena

a month ago

ALS pipeline suffers a major hit as Biogen’s Tofersen fails phase iii trial

BIIB

Morningstar Research

a month ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
BIIB

Zacks

a month ago

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
BIIB

Zacks

a month ago

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
BIIB

Zacks

a month ago

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
BIIB

Zacks

a month ago

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab

Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower
BIIB

Investor's Business Daily

a month ago

Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower

FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.
BIIB

Barrons.com

a month ago

FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.

Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
BIIB

Zacks

a month ago

Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod

Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say
BIIB

BioPharma Dive

2 months ago

Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say

FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug
BIIB

Investor's Business Daily

2 months ago

FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug

FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
BIIB

Yahoo Finance

2 months ago

FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment

Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
BIIB

Investor's Business Daily

2 months ago

Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug

Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
BIIB

Zacks

2 months ago

Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance

BIIB

MT Newswires

2 months ago

Biogen, Eisai Say Alzheimer's Maintenance Treatment Application Accepted by US FDA

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
BIIB

GlobeNewswire

2 months ago

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Italian energy company targets Britain for fleet of 20 mini-nukes
BIIB

The Telegraph

2 months ago

Italian energy company targets Britain for fleet of 20 mini-nukes

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
BIIB

Motley Fool

2 months ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Seoul resumes loudspeaker propaganda against North
BIIB

AFP

2 months ago

Seoul resumes loudspeaker propaganda against North

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss
BIIB

Simply Wall St.

2 months ago

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

American Software Full Year 2024 Earnings: EPS Beats Expectations
BIIB

Simply Wall St.

2 months ago

American Software Full Year 2024 Earnings: EPS Beats Expectations

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns
BIIB

Simply Wall St.

2 months ago

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
BIIB

Simply Wall St.

2 months ago

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

3 Mistakes That Can Get Your Costco Membership Canceled
BIIB

Motley Fool

2 months ago

3 Mistakes That Can Get Your Costco Membership Canceled

Eli Lilly Is Trading At A Record High Ahead Of A Key FDA Meeting — Is It A Buy?
BIIB

Investor's Business Daily

2 months ago

Eli Lilly Is Trading At A Record High Ahead Of A Key FDA Meeting — Is It A Buy?

BIIB

Morningstar Research

2 months ago

Analyst Report: Biogen Inc.

Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?
BIIB

Zacks

2 months ago

Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?

Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
BIIB

Zacks

2 months ago

Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates

Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
BIIB

Zacks

2 months ago

Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?

Here's Why Biogen Inc. (BIIB) is a Strong Momentum Stock
BIIB

Zacks

2 months ago

Here's Why Biogen Inc. (BIIB) is a Strong Momentum Stock

BIIB

MT Newswires

2 months ago

Wedbush Adjusts Price Target on Biogen to $215 From $219

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel
BIIB

GlobeNewswire

2 months ago

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
BIIB

Benzinga

2 months ago

Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder

Repligen (RGEN) Down 10.9% Since Last Earnings Report: Can It Rebound?
BIIB

Zacks

2 months ago

Repligen (RGEN) Down 10.9% Since Last Earnings Report: Can It Rebound?

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
BIIB

Zacks

2 months ago

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

How To Invest: Using Shorter-Term Moving Averages To Trade Stocks
BIIB

Investor's Business Daily

2 months ago

How To Invest: Using Shorter-Term Moving Averages To Trade Stocks

European Commission approves Biogen’s QALSODY for ALS treatment
BIIB

Pharmaceutical Technology

2 months ago

European Commission approves Biogen’s QALSODY for ALS treatment

BIIB

MT Newswires

2 months ago

Biogen Gets European Commission Approval for Qalsody

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
BIIB

GlobeNewswire

2 months ago

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

Is Eli Lilly Stock A Buy On A Recent Crohn's Disease-Related Rally?
BIIB

Investor's Business Daily

2 months ago

Is Eli Lilly Stock A Buy On A Recent Crohn's Disease-Related Rally?

Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?
BIIB

Zacks

2 months ago

Qiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?

Interim results of IGNAZ trial sheds positive light on felzartamab for IgAN
BIIB

Clinical Trials Arena

2 months ago

Interim results of IGNAZ trial sheds positive light on felzartamab for IgAN

Is Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals?
BIIB

Simply Wall St.

2 months ago

Is Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals?

South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s
BIIB

Pharmaceutical Technology

2 months ago

South Korea’s MFDS approves Eisai-Biogen’s LEQEMBI for Alzheimer’s

Share on Social Networks: